SCHAUMBURG, IL. Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched ondansetron in 5% dextrose injection in premix bags, an antiemetic and selective 5-HT³ receptor antagonist used to prevent nausea and vomiting caused by chemotherapy.  Sagent’s ondansetron in 5% dextrose injection in premix bags is the generic equivalent of GlaxoSmithKline’s ZOFRAN^® Injection Premixed.  Sagent will begin marketing and shipping ondansetron in 5% dextrose injection premix bags immediately.

“Ondansetron premix is an important addition to our rapidly growing line of ready-to-use products,” said Jeffrey M. Yordon, Sagent’s chief executive officer, founder, and chairman of the board.  “Our ondansetron premix bag provides healthcare workers with enhanced packaging features to aid in rapid and accurate product identification and administration.”

Sagent will offer ondansetron in 5% dextrose injection in 32 mg per 50 mL single dose premix bags.

About Ondansetron

 

Ondansetron in 5% dextrose injection is the generic equivalent of GlaxoSmithKline’s ZOFRAN^® Injection Premixed.  Ondansetron injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin.  Efficacy of the 32 mg single dose beyond 24 hours in these patients has not been established.  The most common adverse effects for patients receiving ondansetron injection may include constipation, dizziness or headache.

The package insert, which is available at www.SagentPharma.com, contains detailed information about the indication, complete side effect profile and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.  Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.  Sagent currently has more than 200 products in development.

To Discover Injectables Excellence™ and learn more about Sagent, please visit www.SagentPharma.com.